Bayer strikes deal with Dimension Therapeutics to develop hemophilia A gene therapy

USA-based venture capital;-backed biotech Dimension Therapeutics has entered into a collaboration with German drug major Bayer (BAYN: DE) for the development and commercialization of a novel gene therapy for the treatment of hemophilia A.

Under the terms of the accord, Dimension will receive an upfront payment of $20 million and will be eligible for potential development and commercialization milestone payments of up to $232 million. Dimension will be responsible for all pre-clinical development activities and the Phase I/IIa clinical trial, with funding from Bayer. Depending on the results of the Phase I/IIa study, Bayer will conduct the confirmatory Phase III trial, make all regulatory submissions, and will have worldwide rights to commercialize the potential future product for the treatment of haemophilia A. Dimension is also eligible to receive tiered royalties based on product sales.

Could add products to Bayer’s hemophilia A portfolio